Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas…More. XCART™ has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.